What should I do if lung adenocarcinoma ros1 is resistant to crizotinib?

In patients with lung adenocarcinomaROS1 gene mutations, the emergence of drug resistance after treatment with crizotinib is a problem that needs attention. Faced with this situation, patients and doctors need to jointly consider the next treatment strategy.

Drug resistance may be due to genetic mutations in tumor cells, which lead to changes in the ROS1 gene that was originally sensitive to crizotinib, making the drug no longer able to effectively inhibit the growth of tumor cells. The emergence of this kind of drug resistance is a common problem during tumor treatment and is also one of the hot spots in current medical research.

After crizotinib resistance is discovered, patients should first undergo a comprehensive disease assessment, including tumor size, location, and whether there is metastasis. At the same time, genetic testing is recommended to determine the specific mechanism of resistance. This helps doctors develop more precise treatment plans for patients.

If the patient's disease progresses slowly or only locally, such as only a slight increase in the size of the lesion or the occurrence of isolated local metastasis (such as a solitary bone metastasis or brain metastasis), then continued treatment with crizotinib may be considered. At the same time, radiation therapy can be performed at the metastatic site to control the development of local lesions.

If the patient develops multiple new metastatic lesions, or the primary lesions increase rapidly, other targeted drugs may need to be replaced for treatment. Currently, a new generation of ROS1 inhibitors such as lorlatinib are available. In addition, patients can also consider using other targeted drugs in combination to enhance the therapeutic effect.

In addition to targeted therapy, patients can also consider other treatments, such as chemotherapy, immunotherapy, etc. Chemotherapy can control the disease by killing or inhibiting the growth of tumor cells. Immunotherapy, on the other hand, activates the patient's own immune system to attack tumor cells.